First Endovascular Neural Interface Eyed By New Firm Synchron
This article was originally published in The Gray Sheet
Executive Summary
The company launched in Silicon Valley on April 21 with plans to develop a device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.
You may also be interested in...
End Of US FDA’s Very Fast Reviews? 2022 Novel Approvals Stayed Close To PDUFA Timeframes
Moderation was a theme of the year in novel approvals, as CDER’s median review time rose for the first time in five years and even the center’s fastest approval took more than seven months.
The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge
First Humira biosimilar launches raise worries about holes in US health system that may let the brand product continue to dominate. If Humira biosimilars can’t get a strong foothold, reform to biosimilar policy for medicines reimbursed through the pharmacy benefit may be necessary if the US wants to rely on these products to bring down the cost of brand biologics.
House Health Subcommittee Chair Prioritizes Affordability, Innovation, Ending COVID PHE
Kentucky Republican Brett Guthrie is strong proponent of health care affordability and innovation in pharmaceuticals and medical devices. He’s also monitoring FDA’s response to drug shortages and infant formula shortages.